Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Combatting New Jersey Auto Casualty Challenges
When an auto injury occurs, insurers often face challenges in coordinating with multiple vendors to address the claim. This is especially true in New Jersey, which has strict requirements that every insurer needs to meet. To discuss this issue, and offer solutions for handling it, is Ben Roberts, vice president, utilization review of Genex.
Plugged-In: EV Collision Insights 2023 Year in Review
2023 ended with electric vehicle (EV) repairable claims frequency at 1.97% in the United States and 2.86% in Canada. That represents an increase of more than 40% in both regions over the previous year. When compared to 2020, the frequency of claims for repairable EVs has more than tripled.
Latest Mitchell Data Shows Continued Increase in Electric Vehicle Collision Claims
Mitchell today announced the publication of its latest trends report: Plugged-In: EV Collision Insights. This issue provides a year-over-year analysis of EV claims volume, which increased in 2023 by more than 40% in the U.S. and Canada.
Enhancing Provider Networks: Coventry's Quality Improvement Program
Optimize Your Provider Network Quality with Coventry's Improvement Program Today!
Rising PTSD claims, wider comp liabilities spotlight importance of treatment guidelines
Mental health experts say that adherence to guidelines for the diagnosis and treatment of PTSD is essential when treating affected workers.
Enlyte and Former Genex Leaders Reach Agreement to Create New IME Business
Enlyte and its Board of Directors have made the strategic decision to transfer its Independent Medical Examination (IME) business and more than 350 employees from Enlyte to the creation of a new, stand-alone IME company, Emperion, Inc. Emperion will be owned by Stone Point Capital, Enlyte’s current shareholder, through its Trident Funds and a management team led by former Genex executives.